TEZSPIRE
Q2 2026 sales rose 42% to $486 million; a Phase 3 study in eosinophilic esophagitis is due to finish in H2 2026.
The numbers
What it is
Asthma medicine that blocks TSLP, developed with AstraZeneca. It is sold as a respiratory biologic and is one of Amgen's main growth products.↗ source
Why it matters to the stock. TEZSPIRE's growth and any new indication, such as eosinophilic esophagitis, extend the product's revenue base beyond asthma.
News
TEZSPIRE meets both co-primary endpoints in Phase 3 eosinophilic esophagitis trial
Amgen and AstraZeneca reported positive topline results from the Phase 3 CROSSING trial of TEZSPIRE in eosinophilic esophagitis on August 27, 2026.
Amgen's 2026 outlook: $38.2B to $39.4B revenue and $22.30 to $23.50 non-GAAP EPS
Alongside its second-quarter results, Amgen set full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues, non-GAAP diluted EPS of $22.30 to $23.50, and GAAP diluted EPS of $15.80 to $17.08.